Search results
Jan 22, 2018 · Celgene has agreed to buy CAR-T specialist Juno Therapeutics for around $9 billion in a deal that instantly makes it a big cheese in this emerging therapeutic category. The definitive terms of the ...
Jan 22, 2018 · Celgene will host a conference call today, January 22, to discuss the strategic acquisition of Juno Therapeutics at 8 a.m. ET. The conference call will be available by webcast on the Investor Relations page of Celgene’s website, www.celgene.com. An audio replay of the call will be available from midnight January 22, 2018 until midnight ...
People also ask
Who owns Juno Therapeutics?
Will Celgene buy Juno Therapeutics?
How does Celgene acquire Juno?
Will Juno acquire jcar017?
Jan 22, 2018 · Juno Therapeutics, the Seattle-based biotech company making cutting-edge cancer immunotherapy treatments, has reached a deal to be acquired by New Jersey-based Celgene for $9 billion, or $87 per ...
Jan 22, 2018 · Celgene Corporation to Acquire Juno Therapeutics, Inc., Advancing Global Leadership in Cellular Immunotherapy ... January 22, to discuss the strategic acquisition of Juno Therapeutics at 8 a.m. ET.
Jan 22, 2018 · January 22, 20188:28 AM PSTUpdated 6 years ago. (Reuters) - Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental ...
Mar 7, 2018 · Celgene bought Juno in a deal valued at about $9 billion. Juno has about 650 employees in its South Lake Union office and a Bothell development plant; both will remain following the acquisition.
Jan 22, 2018 · Celgene Corp. will acquire Juno Therapeutics Inc. and its pipeline of cancer cell therapies for $9 billion, betting on the continued emergence of CAR-T at a time when concerns over future growth have shaken investor confidence in the blue chip biotech. At a takeout price of $87 per share, the deal values Juno at a nearly 91% premium to the ...
